Strides Begins Biosimilar Filings With Teriparatide
Expands COVID-19 Ambitions
Executive Summary
Strides files for a biosimilar to Eli Lilly’s Forteo (teriparatide) in the EU, marking the beginning of its journey in the biosimilars segment. Meanwhile, it hopes to enter a manufacturing tie-up with COVID-19 vaccine players in H2 while also planning a launch of favipiravir in markets outside India.
You may also be interested in...
Strides’ Stelis Completes $195m Funding Rounds
Strides says its Stelis biopharmaceuticals unit is now well-placed to pursue key growth initiatives after completing Series B and Series C funding rounds worth $195m that value the business at around $350m overall.
Muted Q2 But Biocon Confident Of Insulin Glargine’s Onward US March
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.
Muted Q2 But Biocon Confident Of Insulin Glargine’s Onward US March
Biocon Biologics upbeat on Lantus follow-on’s long revenue stream and prospects for interchangeability, while operational challenges resulted in some supply constraints during the fiscal second quarter.